Clinical Study

Thyrotoxic Atrial Fibrillation: Factors Associated with Persistence and Risk of Ischemic Stroke

Table 1

Comparison of clinical characteristics of patients with spontaneous reversal of atrial fibrillation to sinus rhythm versus patients with persistent atrial fibrillation.

Spontaneous reversalPersistent atrial fibrillation value

8944
Age (years)64 (15)63 (16)0.893
Sex (female)55 (61.8%)20 (45.5%)0.074
History of smoking39 (42.3%)29 (65.9%)0.019
BMI (kg/m2)22.1 (3.7)22.1 (3.9)0.938
Systolic BP (mmHg)148 (26)144 (24)0.374
Diastolic BP (mmHg)82 (18)80 (16)0.659
Heart rate on 1st ECG (bpm)132 (32)128 (27)0.521
DM14 (15.7%)9 (20.5%)0.498
HT31 (34.8%)17 (38.6%)0.667
IHD7 (7.9%)1 (2.3%)0.270
Median months (IQR) of follow-up40 (19–71)48 (26–87)0.006
Etiology of thyrotoxicosis
 (i) Graves’ disease43 (48.3%)27 (61.4%)0.347
 (ii) Multinodular goitre37 (41.6%)13 (29.5%)
 (iii) Others/indeterminate9 (10.1%)4 (9.1%)
fT4 (xULN)2.33 (1.03)1.93 (0.86)0.033
fT4 (pmol/l)
 (i) Before 6/201049.0 (19.4) ()40.8 (15.0) ()0.064
 (ii) After 6/201042.5 (19.0) ()36.2 (17.6) ()0.233
Positive anti-TPO antibody37 (54.4%) ()19 (65.5) ()0.311
Positive anti-Tg antibody25 (36.2%) ()15 (51.7%) ()0.154
Heart failure37 (41.6%)26 (59.1%)0.057
Dilated cardiomyopathy3 (3.4%)5 (11.4%)0.115
Having a past episode of thyrotoxicosis21 (23.6%)18 (40.9%)0.039
Median time to achieve euthyroidism (months, IQR)2 (1–3)2 (1–3)0.512
Radioactive iodine as treatment for thyrotoxicosis35 (39.3%)21 (47.7%)0.356
Beta blockers54 (60.7%)23 (52.3%)0.356
ACEI/ARB18 (20.2%)16 (36.4%)0.045
Digitalis18 (20.2%)19 (43.2%)0.005
Aspirin31 (34.8%)18 (40.9%)0.494
Warfarin6 (6.7%)6 (13.6%)0.192
Incident ischaemic stroke9 (10.1%)7 (15.9%)0.506

Note. bpm: beats per minute; BMI: body mass index; BP: blood pressure; DM: diabetes mellitus; IHD: ischemic heart disease; ULN: upper limit of normal; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker. Values are expressed as (%) or mean (SD) unless otherwise specified; .